Immuneering (IMRX)
(Delayed Data from NSDQ)
$1.20 USD
+0.09 (8.11%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMRX 1.20 +0.09(8.11%)
Will IMRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMRX
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
Other News for IMRX
12 Health Care Stocks Moving In Tuesday's After-Market Session
Immuneering to Present at the Jefferies Global Healthcare Conference
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
Buy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data Events
Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)